Table 2 Infection characteristics and treatmenta
Partial Oral Therapy | All Intravenous Therapy | Total | |
|---|---|---|---|
Characteristic | (n = 148) | (n = 101) | (N = 249) |
Setting | |||
Community-onset | 108 (73) | 69 (68) | 177 (71) |
Hospital-onset | 5 (3) | 12 (12) | 17 (7) |
Healthcare-associated, community-onset | 35 (24) | 20 (20) | 55 (22) |
S. aureus susceptibility | |||
Methicillin-susceptible | 101 (69) | 67 (68) | 168 (69) |
Methicillin-resistant | 43 (30) | 31(31) | 74 (30) |
Unknown | 2 (1) | 1 (1) | 3 (1) |
Infection type | |||
Bacteremia | 18 (12) | 68 (67) | 86 (35) |
Uncomplicated bacteremia | 3 (2) | 15 (15) | 18 (7) |
Complicated bacteremia | 5 (3) | 21 (21) | 26 (10) |
Infective endocarditis | 2 (1) | 15 (15) | 17 (7) |
Osteomyelitis | 6 (4) | 15 (15) | 21 (8) |
Septic arthritis | 2 (1) | 2 (2) | 4 (2) |
Osteomyelitis without bacteremia | 120 (81) | 32 (32) | 152 (61) |
Septic arthritis without bacteremiab | 10 (7) | 1 (1) | 11 (4) |
Echocardiogram | |||
Transthoracic | 29 (20) | 73 (73) | 102 (41) |
Transesophageal | 5 (3) | 26 (26) | 31 (12) |
Definitive intravenous antibioticc | |||
Vancomycin | 75 (51) | 34 (34) | 109 (44) |
Cefazolin | 36 (24) | 53 (53) | 89 (36) |
Dalbavancin | 1 (1) | 16 (16) | 17 (7) |
Otherd | 24 (16) | 20 (20) | 44 (18) |
Definitive oral antibiotic(s)c | |||
Clindamycin | 52 (35) | 1 (1) | 53 (21) |
Levofloxacin | 52 (35) | 0 | 52 (21) |
Linezolid | 28 (19) | 0 | 28 (11) |
Rifampin | 28 (19) | 0 | 28 (11) |
Trimethoprim-sulfamethoxazole | 8 (5) | 0 | 8 (3) |
Amoxicillin-clavulanate | 16 (11) | 0 | 16 (6) |
Doxycycline | 12 (8) | 0 | 12 (5) |
Total duration of antibiotics, median (IQR) | 30 (14–42) | 31 (14–42) | 30 (14–32) |
Duration of IV antibiotics prior to oral transition, median (IQR) | 4 (3–11) | - | - |